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Abstract: Topical drug delivery is an attractive alternative to conventional methods because of
advantages such as non-invasive delivery, by-pass of first pass metabolism, and improved patient
compliance. However, several factors such as skin, physicochemical properties of the drug, and vehicle
characteristics influence the permeation. Within a formulation, critical factors such as concentration
of drug, physical state of drug in the formulation, and organoleptic properties affect the flux across the
skin. The aim of the study was to develop and investigate topical semisolid preparations (creams and
gels) with ibuprofen as the model drug and investigate the effect of various formulation parameters
on the in-vitro performance across the Strat-M® membrane using flow-through cells. In addition,
the physical stability of the developed formulations was investigated by studying viscosity, pH,
and appearance. All the formulations developed in the study had appealing appearance with smooth
texture and no signs of separation. Viscosity and pH of the formulations were acceptable. Cumulative
amount of drug permeated at the end of 24 h was highest for clear gel (3% w/w ibuprofen; F6:
739.6 ± 36.1 µg/cm2 ) followed by cream with high concentration of ibuprofen in suspended form
(5% w/w; F3: 320.8 ± 17.53 µg/cm2 ), emulgel (3% w/w ibuprofen; F5: 178.5 ± 34.5 µg/cm2 ), and cream
with solubilized ibuprofen (3% w/w; F2A: 163.2 ± 9.36 µg/cm2 ). Results from this study showed that
permeation of ibuprofen was significantly influenced by formulation parameters such as concentration
of ibuprofen (3% vs. 5% w/w), physical state of ibuprofen (solubilized vs. suspended), formulation
type (cream vs. gel), mucoadhesive agents, and viscosity (high vs. low). Thus, findings from this
study indicate that pharmaceutical formulation scientists should explore these critical factors during
the early development of any new topical drug product in order to meet pre-determined quality
target product profile.
Keywords: topical cream; topical gel; emulgel; ibuprofen; semi-solid topical formulations; permeation;
Strat-M® ; Permegear flow-through cells; formulation parameters; topical bioavailability; Quality
Target Product Profile (QTPP); in-vitro permeation test (IVPT)
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1. Introduction
Topical/transdermal drug delivery refers to the delivery of drugs via skin and is an attractive
alternative to conventional methods such as oral and parenteral routes. Advantages associated
with topical/transdermal delivery include non-invasive delivery, bypass of first pass metabolism,
prolonged duration of action, reduced dosing frequency, constant levels of drug in the plasma,
reduced drug toxicity/adverse events, improved patient compliance, and others [1–3]. However,
skin acts as a major barrier for the entry of drugs and foreign compounds due to the presence of
stratum corneum, a thin keratin-rich layer (15 µm) of dead cells embedded in an intricate lipid
environment made of cholesterol, ceramides, and free fatty acids [4–6]. In addition, several other
factors such as physicochemical properties of the drug (lipophilicity, solubility, molecular weight or
size, and hydrogen bonding) and characteristics of a formulation/vehicle or a drug delivery system
influence the permeation [7]. To overcome these challenges, several physical and chemical methods
have been employed to enhance the transport of drugs through the skin. Physical methods include
approaches such as microneedles, thermal ablation, radiofrequency, iontophoresis, ballistic liquid
jets, laser, and others [4,8–11]. However, these methods are known to cause irritation to the skin
due to mechanical, thermal, magnetic, and electrical energy [8]. Chemical methods include the use
of penetration enhancers such as propylene glycol, ethanol, transcutol, and others to enhance the
drug transport through the skin. They increase the diffusion of drugs through the skin by interacting
and altering the complex structure of skin and thus enhancing the partition of drug into different
layers [12,13]. Several penetration enhancers have been approved in the market, but their application in
topical and transdermal formulations is limited as there is no clear understanding on how these agents
enhance drug transport [14]. In addition to penetration enhancers, several other excipients/additives
such as solvents, co-solvents, surfactants, humectants, thickening agents, and others are used in
the development of topical/transdermal formulation. These agents act as inactive ingredients and
control the extent of absorption (thermodynamic activity and partition coefficient), maintain the
viscosity and pH, improve the stability as well as organoleptic properties, and increase the bulk of the
formulation [15,16]. Similar to every other dosage form, topical formulation development program also
involves pre-formulation development, formulation development, performance (in vitro and in vivo),
and stability. A well-designed Quality Target Product Profile (QTPP) provides a structure to ensure
that a formulation scientist embarks on a product development program that is efficient and yet defines
a listing of all relevant medical, technical, and scientific information required to reach the desired
commercial development outcome [17]. However, formulation scientists face several challenges while
developing a drug product with desirable QTPP. In case of topical product development, achieving the
target flux is a challenge as it is dependent of several factors.
Percutaneous drug absorption is a process which involves steps such as (i) dissolution and release
of drug from the vehicle/formulation, (ii) partition of drug into the stratum corneum, (iii) diffusion
of the solubilized drug across the stratum corneum, and (iv) penetration of drug into the layers
of the skin [18]. The goal in the development of any topical/transdermal drug formulation is to
achieve maximum flux across the skin without any drug build-up. Critical factors which influence
the flux across the skin include concentration of drug in the vehicle/formulation, physical state of
drug in the formulation, and other formulation properties. Concentration of drug in the formulation
is important as a proportional increase in the flux can be achieved by increasing the concentration
of the dissolved drug. According to Fick’s law of diffusion (Equation (1)), at a higher concentration
above the solubility, the excess drug in the formulation acts as a reservoir and helps in maintaining
constant flux for a prolonged period and thus increases the permeation [19]. Physical state of the drug
in the formulation (solubilized drug vs. dispersed/suspended drug) can also significantly affect the
permeation. It is known that greater flux is achieved when the drug is in solubilized form compared
to suspended form. Enhanced permeation is attributed to increase in thermodynamic activity and
partition with solubilized drug. Thus, the solubilized systems have advantages such as increased
efficacy at lower concentrations, low drug irritation potential and cost efficient [16]. In addition to
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the above, formulation properties such as type of formulation (monophasic vs. multiphasic systems),
viscosity, pH, and other organoleptic properties significantly affect the transport of drug across the
skin. Therefore, pharmaceutical formulation scientists must consider all the above factors in the
development of any new topical drug product. Since the inception of topical dosage forms, numerous
excipients have been investigated for their application in conventional dosage forms, such as creams,
gels, and ointments. Although several excipients have been approved by the United States Food
and Drug Administration (USFDA) for topical use, formulation scientists face challenges in the
development of topical drug product with desired permeation profile. In addition, efforts have also
been made in development of novel formulations, such as microemulsions, nanoparticulate drug
delivery systems, eutectic mixtures, patches, and others to enhance the permeation of drugs across the
skin [20,21]. In general, there is a lack of scientific evaluation on how the formulation properties, such as
concentration of drug, physical state of the drug, and formulation type, influence the bioavailability of
conventional topical dosage forms, such as creams and gels. Although several studies have evaluated
the effect of formulation properties on transdermal permeation of drugs, the scientific data show
that the research was limited to only one factor, such as concentration of drug [22], concentration of
excipients [7,23], and formulation type [24,25]. Therefore, the current study was designed to provide
ready information to the formulators who design and develop topical semisolid formulations on the
impact of formulation properties (concentration of drug, physical state of the drug, mucoadhesive
agents, and formulation type) on transdermal permeation.
J = K·∆C =

D·Kp ·∆C
h

(1)

Equation (1): Fick’s law of diffusion, where J is the steady-state flux of the drug molecule through
the skin (µg/cm2 ·h), K is the permeability coefficient (cm/s), ∆C is the difference in concentration
(µg/cm3 ), D is the diffusion coefficient (cm2 /s), Kp is the apparent partition coefficient, and h is the
thickness of the layer of skin (cm).
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat local pain and inflammation
associated with injuries, rheumatoid arthritis, osteoarthritis, and other musculoskeletal problems [7,26].
Although, NSAIDs are very effective, their oral absorption is associated with severe gastric irritation
leading to gastric bleeding and ulcers. Therefore, topical/transdermal delivery of NSAIDs is
preferred as it bypasses hepatic first pass metabolism and also results in targeted effect at the
site of inflammation/pain [24]. Majority of the NSAIDs (salicylates, acetic acid derivatives, enol
acid derivatives, and propionic acid derivatives) approved by USFDA have similar physicochemical
properties (molecular mass, logP, and pKa ) [27–30]. Hence, it can be assumed that there may be
similarities in transdermal permeation for these compounds [29]. Among these agents, ibuprofen is the
most commonly used NSAID. Ibuprofen (α-methyl-4-(2-methylpropyl) benzeneacetic acid) is a weak
acid (pKa 4.5–4.6), thus the pH of the skin (~4.8) favors passive diffusion as majority of the molecules
will be in unionized form. However, poor aqueous solubility (0.084 and 0.685 mg/L at pH 4.5 and 5.54,
respectively) limits the skin permeation of ibuprofen. Ibuprofen is considered as an attractive candidate
for topical/percutaneous delivery due to the physicochemical properties (low molecular weight (MW:
206.29 g·mol−1 ), suitable partition coefficient (logP: 3.68), and short elimination half-life (t1/2 2–4 h), [7].
Currently, topical formulations of ibuprofen are not approved in the United States. Therefore, taking
into account all the above factors and availability of drug for research purposes, ibuprofen was chosen
as the model drug for our study. The main goal of the study was to prepare semisolid formulations
and investigate the effect of concentration of drug, formulation type and physical state of drug on
transdermal permeation of ibuprofen. All the excipients (except Sepineo SE 68) used were approved
by the USFDA for topical use and were within the limits listed in the inactive ingredient database.
In the present study, we have developed ibuprofen topical creams at two concentrations (3% and 5%
w/w)—emulgel (3% w/w) and clear non-aqueous gel (3% w/w). Further, in-vitro permeation studies
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were performed across the Strat-M® membrane to study the effect of various formulation parameters
on the permeation of ibuprofen.
2. Materials
Ibuprofen, hydroxy propyl methyl cellulose (HPMC) (MW: 86,000, viscosity 4000 cps at 2%
solution), and hydroxy propyl cellulose were purchased from Acros Organics (Fair Lawn, NJ, USA).
Absolute ethanol, sorbitan monolaurate (Span 20), sodium chloride, glacial acetic acid, acetonitrile
(HPLC grade) were procured from Fisher Chemicals (Fair Lawn, NJ, USA). Deionized water used
in all the experiments was obtained from in-house Milli-Q® IQ 7000 Ultrapure Water System (EMD
Millipore, Bedford, MA, USA). Mineral oil NF and white petrolatum were purchased from PCCA
(Houston, TX, USA). Tefose® 63 (mixture of PEG-6 stearate NF/JPE and Ethylene glycol palmitostearate
EP/NF/JPE) and Transcutol® (Diethylene glycol monoethyl ether EP/NF) were gift samples from
Gattefossé (Paramus, NJ, USA). Kollicream® IPM (isopropyl myristate), Kollicream® OA (oleyl
alcohol), Kollisolv® MCT 70 (medium-chain triglycerides), Kollisolv® PEG 400 (polyethylene glycol
400), Kollisolv® PG (propylene glycol), Kolliphor® CS 20 (macrogol cetostearyl ether 20/polyoxyl 20
cetostearyl ether), Kolliphor® PS 80 (polysorbate 80), Kolliphor® CS A (cetostearyl alcohol (type A)),
Kolliwax® CA (cetyl alcohol), and Kolliwax® SA (stearyl alcohol) were generous samples from BASF
(Tarrytown, NY, USA). Glycerol monostearate was obtained from Alfa Aesar (Ward Hill, MA, USA).
Strat-M® membrane and glycerol were procured from Sigma-Aldrich (St. Louis, MO, USA). Carbopol
974P (Carbomer Homopolymer Type B) was a sample from Lubrizol Life Sciences (Cleveland, OH,
USA). Sepineo™ P600 (acrylamide/sodium acryloyldimethyl taurate copolymer/isohexadecane and
Polysorbate 80) and Sepineo™ SE 68 (cetearyl alcohol, cetearyl glucoside) were gift samples from
Seppic Inc (Fairfield, NJ, USA).
3. Methods
3.1. Solubility of Ibuprofen in Solvents
The solubility of ibuprofen in liquid excipients was determined using visual solubility protocol.
In this method, the excipients were accurately weighed (2.5 g) in individually-labelled 20 mL scintillation
vials. To these vials, accurately weighed aliquots of ibuprofen (~5 mg for glycerol due to poor solubility
and ~25 mg for other excipients) was added and tightly closed. Further, the vials were placed in a
shaking water bath (Fisher Scientific, Waltham, MA, USA) maintained at 25 ◦ C for at least 15 min
to allow proper mixing. After 15 min, the vials were visually inspected, and additional aliquots of
ibuprofen were added periodically (every 15 min) until saturation was achieved. Following this,
the vials were placed in the shaking water bath for 24 h and visually inspected the following day.
The final weight of the vials was measured to determine the approximate solubility of ibuprofen in
each excipient and reported as mg/g and percentage (%).
3.2. Formulation of Ibuprofen Creams and Gels
3.2.1. Optimization of Formulations
Optimization of all the formulations was performed by evaluating the effect of different
concentrations of excipients on the stability, excipient instability, viscosity, and any visual changes in
the formulations (Appendix A). After optimization, stable formulations which provided acceptable
appearance and viscosity were chosen for further evaluation. Compositions of all the optimized creams,
emulgel and clear gel are provided in Table 1, Table 2, and Table 3, respectively. All the formulations
had differences in composition since the main aim of this study was to evaluate on how formulation
parameters such as concentration and physical state of the drug, formulation type and mucoadhesive
agents influence the permeation of ibuprofen.
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Table 1. Composition of optimized creams in the study.
Formulation

Components
Ibuprofen
Propylene glycol
Oleyl alcohol
Isopropyl myristate
Transcutol
Mineral oil
White petrolatum
Polyethylene glycol 400
Medium chain
triglycerides
Glycerol
Span 20
Kolliphor polysorbate 80
Kolliphor CS 20
Glycerol monostearate
Cetyl alcohol
Stearyl alcohol
Cetostearyl alcohol
Sepineo SE68
Sepineo P600
Tefose 63
HPMC
Carbopol 974
Water

F1A (%w/w)

F1B (%w/w)

F2A (%w/w)

F2B (%w/w)

F3 (%w/w)

F4 (%w/w)

3
15
10
-

3
15
10
-

3
5
10
-

3
5
10
-

5
10
7
10

5
15
-

-

-

-

-

-

10

3.8
3.3
7
5
5
47.9

3.8
3.3
7
5
52.9

4.1
2.5
10
1
64.4

4.1
2.5
10
65.4

4.7
1.3
5
4
8
45

5
5
1.1
7
0.5
51.4

Table 2. Composition of optimized Emulgel in the study.
Components
Ibuprofen
Ethanol
Sepineo P600
Water

Formulation
F5 (%w/w)
3
30
4
63

Table 3. Composition of optimized clear non-aqueous gel in the study.
Components
Ibuprofen
Propylene glycol
Ethanol
Glycerol
Transcutol
Hydroxy propyl cellulose
Polyethylene glycol 400

Formulation
F6 (%w/w)
3
15
10
10
15
4
43

3.2.2. Formulation of Creams
Compositions of the creams developed is provided in Table 1. Ibuprofen creams were developed
at two different strengths (3% w/w (F1A, F1B, F2A, F2B) and 5% w/w (F3, F4)) using a water-in-oil
(w/o) emulsion method. Briefly, ibuprofen was accurately weighed and transferred into a 250 mL
beaker containing all the required oil phase components for each formulation. In another 100 mL
beaker, accurately weighed water soluble components were dissolved in water. Both the beakers were
placed in a water bath and heated to 65 ± 2 ◦ C. Once both the phases reached approximately similar
temperature, the aqueous phase was added to the oil phase and homogenized at 5000 rpm using a
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high shear homogenizer (Fisherbrand™ 850, Waltham, MA, USA) for 10 min to form an emulsion.
After homogenization, the emulsion was allowed to cool down to room temperature by mixing it
using an overhead stirrer (IKA RW20 Digital, Wilmington, NC, USA) at 300 rpm for 2 h until a smooth
cream was obtained. Sepineo P600 was added to the mixture during the process of homogenization for
formulations F3 and F5.
3.2.3. Formulation of Emulgel
Composition of ibuprofen emulgel (F5) (3% w/w) is provided in Table 2. Ibuprofen (3 g) was
dissolved in ethanol (30 mL) and water was added to ibuprofen solution. To this mixture, accurately
weighed Sepineo P600 was added immediately and vigorously mixed using a glass rod until a smooth
emulgel was formed.
3.2.4. Formulation of Clear Non-Aqueous Gel
Composition of ibuprofen clear non aqueous gel (F6) (3% w/w) is provided in Table 3. Ibuprofen
was weighed and added to a mixture of propylene glycol, ethanol, transcutol, and glycerin to obtain a
clear solution. To this clear solution, PEG 400 was added and mixed on a magnetic stirrer. Accurately
weighed HPC (4 g) was dispersed in the mixture and allowed to thicken at room temperature using an
overhead mixer (IKA RW20 Digital, Wilmington, NC, USA) at 500 rpm for 2 h.
3.3. Polarized Light Microscopy
Polarized light microscopy was used to study the microscopic features of the optimized creams and
gels. All the formulations were applied on a microscopic glass slide and evenly spread with a coverslip.
The cover slipped slides were observed under Amscope® PZ300 series polarized light microscope
(Amscope, Irvine, CA, USA) in the transmission mode at 180× magnification and photomicrographs
were captured on a laboratory PC.
3.4. HPLC Analysis of Ibuprofen
The amount of ibuprofen in the samples was quantified using Waters Alliance e2695 HPLC
equipped with 2998 photodiode array detector and Empower 3.0 software. The analysis was carried out
on a reverse phase Phenomenex® C18 column (250 × 4.6 mm; 5 µm particle size) at 25 ◦ C. The mobile
phase was a mixture (60:40) of acetonitrile and water (adjusted to pH 3.8 with acetic acid) at a constant
flow rate of 1.5 mL/min. Samples (60 µL) were injected into the column using autosampler and
monitored at 220 nm. Retention time of ibuprofen was 6.5 min. All the samples injected were filtered
through 0.45 µm membrane filter.
3.5. Measurement of Viscosity and pH
Rheological experiments were conducted to measure the viscosity of the optimized formulations.
Measurements were performed at room temperature using a Viscolead-one digital viscometer (Fungilab
Inc. New York, NY, USA) equipped with a spindle rotor (R6) set at 20 rpm. The method was validated
by using 2% HPMC gel (4000 cps) as a control. The pH of the formulations was evaluated on day 0 and
day 60 using a calibrated Mettler Toledo InLab® pH meter equipped with LE422 micro pH electrode
(Mettler Toledo, Columbus, OH, USA).
3.6. In-Vitro Permeation Studies
In-vitro permeation studies were conducted using a PermeGear®ILC-07 automated system
(PermeGear, Riegelsville, PA, USA) equipped with seven in-line flow-through diffusion cells, made of
Kel-F. Each diffusion cell had a donor and receptor chamber clamped with threaded rods and adjustable
locking nuts. Receptor chambers (volume: 254 µL receptor) had inlet and outlet ports connected to the
Tygon tubings having 1/4-28 HPLC fittings. Temperature of the cells was maintained at 32 ◦ C using

Pharmaceutics 2020, 12, 151

7 of 19

Pharmaceutics 2020, 12, x

7 of 19

Julabo BC4 circulating water bath (Seelbach, Germany). Diameter of the diffusional area was 1 cm
(total diffusional area: 0.785 cm2 ) and the cells2 were connected to a 7-channel peristaltic pump®IPC
area was 1 cm (total diffusional area: 0.785 cm ) and the cells were connected to a 7-channel peristaltic
(Ismatec, Zurich, Switzerland) which draws receptor solution from a reservoir (Figure 1). Strat-M®
pump® IPC (Ismatec, Zurich, Switzerland) which draws receptor solution from a reservoir (Figure
was used as
a diffusion membrane, which was mounted on the cells and sandwiched between the
1). Strat-M® was used as a diffusion membrane, which was mounted on the cells and sandwiched
donor and receptor chambers using the adjustable locking nuts. Formulations (~10 mg ibuprofen)
between the donor and receptor chambers using the adjustable locking nuts. Formulations (~10 mg
were placed on the diffusion membrane and the receptor fluid (10% v/v ethanol) was allowed to flow at
ibuprofen) were placed on the diffusion membrane and the receptor fluid (10% v/v ethanol) was
a rate of 4 mL/h for 24 h. At pre-determined time intervals, the receptor fluid was collected in 20 mL
allowed to flow at a rate of 4 mL/h for 24 h. At pre-determined time intervals, the receptor fluid was
scintillation vials and analyzed using HPLC to determine the amount of ibuprofen permeated through
collected in 20 mL scintillation vials and analyzed using HPLC to determine the amount of ibuprofen
the Strat-M® membrane.
permeated through the Strat-M® membrane.

Figure 1. Permegear ILC-07® automated flow-through cells.
Figure 1. Permegear ILC-07® automated flow-through cells.

3.7. Permeation Data Analysis
3.7. Permeation Data Analysis
The permeation profile from the formulations was plotted as cumulative amount of ibuprofen
The permeation
profile
the2 /h)
formulations
was(h)
plotted
as cumulative
amount
of ibuprofen
permeated
vs. time. The
fluxfrom
(µg/cm
and lag-time
estimates
were generated
using
Skin and
permeated Permeation
vs. time. TheData
fluxAnalysis
(µg/cm2/h)
and lag-time
(h) estimates
were
generated
using
Membrane
(SAMPA)
software,
version 1.04,
a free
software
toolSkin
usedand
for
Membrane
Permeation
Data
Analysis
(SAMPA)
software,
version
1.04,
a
free
software
tool
used
for
skin and membrane permeation data analysis [31].
skin and membrane permeation data analysis [31].
3.8. Physical Stability
3.8. Physical Stability
Physical stability studies were conducted for all the formulations at 25 ± 2 ◦ C and at 40 ± 2 ◦ C.
All the
samples
were transferred
to glass
scintillation
closed tightlyatand
at 25at±40
2 ◦±C2and
Physical
stability
studies were
conducted
for allvials,
the formulations
25 ±stored
2 °C and
°C.
◦
40
2 samples
C. Samples
were
evaluatedtofor
stability,
changes
in color,
and
any other
physical
for
All±the
were
transferred
glass
scintillation
vials,
closed
tightly
and stored
at instability
25 ± 2 °C and
90
40 days.
± 2 °C. Samples were evaluated for stability, changes in color, and any other physical instability
for 90 days.
3.9. Statistical Analysis

3.9. Statistical
Analysis
All the data
was statistically analyzed using GraphPad Prism software (Version 5.0, San Diego,
CA, USA).
data analysis
was performed
using SAMPA
1.04.
p-value
of
All thePermeation
data was statistically
analyzed
using GraphPad
Prismsoftware,
softwareversion
(Version
5.0,ASan
Diego,
<0.05
was
considered
as
statistically
significant.
CA, USA). Permeation data analysis was performed using SAMPA software, version 1.04. A p-value
of <0.05 was considered as statistically significant.
4. Results and Discussion

4. Results
andinDiscussion
4.1.
Solubility
Solvents
The solubility
of ibuprofen in different solvents is provided in Table 4. Results show that transcutol
4.1. Solubility
in Solvents
and propylene glycol provided the greater solubility (300 mg/g), whereas glycerol provided lowest
The solubility of ibuprofen in different solvents is provided in Table 4. Results show that
solubility of ibuprofen (4 mg/g). The order of ibuprofen solubility in various solvents was transcutol
transcutol and propylene glycol provided the greater solubility (300 mg/g), whereas glycerol
provided lowest solubility of ibuprofen (4 mg/g). The order of ibuprofen solubility in various solvents
was transcutol = propylene glycol > isopropyl myristate > polyethylene glycol 400 > oleyl alcohol =
polysorbate 80 > medium chain triglycerides > mineral oil > glycerol. Results from the solubility
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= propylene glycol > isopropyl myristate > polyethylene glycol 400 > oleyl alcohol = polysorbate
80 > medium chain triglycerides > mineral oil > glycerol. Results from the solubility studies are in
agreement with the literature where solvents/co-solvents such as transcutol, propylene glycol, oleyl
alcohol, and isopropyl myristate enhance the solubility of poorly-soluble compounds [1].
Table 4. Visual solubility of ibuprofen in solvents.
Excipient

Ibuprofen Solubility in
Excipient (mg/g)

Percentage (%)

Transcutol
Propylene glycol (Kollicream®PG)
Isopropyl myristate
Oleyl alcohol (Kollicream®OA)
MCT 70 (medium chain triglycerides)
Mineral oil
PEG 400
Glycerol
Kolliphor®PS 80

300
300
200
180
140
60
190
4
180

30
30
20
18
14
6
19
0.4
18

4.2. pH and Viscosity
All the optimized formulations developed in the study had appealing appearance with smooth
texture and no signs of phase separation. Physical evaluation was done by pressing a small quantity
of formulation between the thumb and index finder. It was observed that all the formulations were
homogeneous and consistent without any coarse particles. The color of all the creams and emulgel
was observed to be white to translucent white (Table 5). Viscosity is an important factor for semisolid
formulations as it may influence the release of drug by altering the diffusion rate from the vehicles.
Results for the viscosity and pH of all the formulations are provided in Table 5. Viscosity of the
formulations ranged from 1872 to 32,655 cps. There was no significant change in the pH of the
formulations over 60 days. The range of pH of the formulations was 4.2 to 5.95, which is close to the
pH of human skin, hence there is minimal risk of skin irritation expected. In addition all excipients
used in the formulations were approved by the USFDA (except Sepineo SE 68) for dermatological
applications, and the concentrations used were within the limits listed in the inactive ingredients
database for approved drug products [32]. Thus, there is minimal potential risk expected of skin
drying, sensory reactions, and alterations in skin hydration with the formulations.
Table 5. Viscosity and pH of ibuprofen creams and gels.
Formulation

Appearance

Viscosity (cps) (Day 0)

Initial pH (Day 0)

pH (Day 60)

F1A
F1B
F2A
F2B
F3
F4

Smooth white cream
Smooth white cream
Smooth white cream
Smooth white cream
Smooth off-white cream
Smooth white cream
Smooth translucent
emulgel
Clear gel

23,451
23,626
32,655
18,954
11,916
11,500

4.44
5.06
4.45
4.57
4.47
4.22

4.49
5.1
4.57
4.46
4.25
4.29

F5
F6

29,659

4.51

4.3

1872

5.95

5.84

4.3. Polarized Light Microscopy
Polarized light microscopy was used to study the presence of ibuprofen particulates in the
formulations. Polarized light microphotographs of all the formulations and control (ibuprofen in
mineral oil) are provided in Figure 2. Table 6 summarizes the observations from polarized light
microphotographs. It can be observed from the images that ibuprofen is in solubilized form (no
crystals) in formulations F2A, F2B, and F6, whereas in all the other formulations presence of crystals in

Table 6. Observations from polarized light microscopy.
Formulation
Observations
F1A
Faint white crystals of ibuprofen suspended in the cream
F1B
Faint white crystals of ibuprofen suspended in the cream
Pharmaceutics
9 of 19
F2A 2020, 12, 151No evidence of ibuprofen crystals indicating solubilized ibuprofen in the cream
F2B
No evidence of ibuprofen crystals indicating solubilized ibuprofen in the cream
F3
High percentage of ibuprofen crystals suspended in the cream due to high concentration of drug
the images
indicate that the drug was
in the formulation.
presence of a higher
F4
Clearsuspended
evidence of ibuprofen
crystals in theMoreover,
cream
F5of ibuprofen crystals in formulations
Rod like ibuprofen
crystals
in higher
the emulgel
number
F3 and
F4 issuspended
due to the
concentration of ibuprofen
F6 F4 (5% w/w) No
evidence to
of other
ibuprofen
crystals indicating
solubilized ibuprofen in the gel
in F3 and
compared
formulations
(3% w/w).

Figure
offormulations.
formulations.Images
Images
were
captured
using
Amscope
Figure2.2.Polarized
Polarized light
light microphotographs
microphotographs of
were
captured
using
Amscope
polarized
magnification.F1A,
F1A,ibuprofen
ibuprofen
suspended
cream
w/w)
with
polarizedlight
lightmicroscope
microscope at
at 180×
180× magnification.
suspended
cream
(3%(3%
w/w)
with
Tefose
cream(3%
(3%w/w)
w/w)without
withoutTefose
Tefose
F2A,
ibuprofen
solubilized
Tefose63,
63,F1B,
F1B,ibuprofen
ibuprofen suspended
suspended cream
63,63,
F2A,
ibuprofen
solubilized
cream
w/w)
with
HPMC,
F2A,F2A,
ibuprofen
solubilized
cream
(3% w/w)
HPMC,HPMC,
F3, ibuprofen
cream(3%
(3%
w/w)
with
HPMC,
ibuprofen
solubilized
cream
(3% without
w/w) without
F3,
suspended
(5% w/w),
F4(5%
ibuprofen
suspended
cream
(5% w/w),
F5, ibuprofen
(3% w/w),
ibuprofen cream
suspended
cream
w/w), F4
ibuprofen
suspended
cream
(5% w/w), emulgel
F5, ibuprofen
F6,
ibuprofen
clear non
aqueous gel
(3%
emulgel
(3% w/w),
F6, ibuprofen
clear
nonw/w).
aqueous gel (3% w/w).
Table 6. Observations from polarized light microscopy.

4.4. In-Vitro Permeation Studies
Formulation

Observations

Cumulative amount and flux of drug permeated through the Strat-M® membrane at the end of
Faint
crystals
ibuprofen
suspended inRecently,
the cream there has been
24 h for F1A
all the formulations is provided
inwhite
Figure
3 andofTable
7, respectively.
F1B
Faint white crystals of ibuprofen suspended in the cream
a significant
rise in using synthetic
artificial membranes (cellulose acetate, Strat-M®, Parallel Artificial
F2A
No evidence of ibuprofen crystals indicating solubilized ibuprofen in the cream
Membrane
(PAMPA))
and 3-D
cultured
human
skin models
as an
alternative
to
F2B Permeability Assay
No evidence
of ibuprofen
crystals
indicating
solubilized
ibuprofen
in the
cream
F3 animal skin
High in
percentage
of ibuprofen of
crystals
suspended
in the cream due
to high concentration
drug
human and
the development
topical
and transdermal
formulations
[33]. In of
2018,
F4
Clear evidence of ibuprofen crystals in the cream
European
Medicines Agency’s draft guideline
on quality and equivalence of topical products has
F5
Rod like ibuprofen crystals suspended in the emulgel
recommended
the
use
of
synthetic
membranes
to
understand
and characterize
of
F6
No evidence of ibuprofenbetter
crystals
indicating solubilized
ibuprofenperformance
in the gel
a finished topical dosage form [34]. Moreover, synthetic membranes are inexpensive and easily
resourced
superior
data reproducibility [35,36]. Therefore, for our studies, Strat-M® was used as
4.4.
In-Vitrowith
Permeation
Studies
a diffusion membrane. Strat-M® is a multilayered synthetic membrane (300 µm thickness) similar to
® membrane at the end of
amount
and flux
of drug permeated
through the
Strat-M
skinCumulative
and made up
of several
tightly-packed
layers of polyester
sulfone.
Several
studies have been
® membrane
24reported
h for all in
thethe
formulations
is provided
Figureof3 Strat-M
and Table
7, respectively.
Recently,
there has been
literature comparing
theinability
to predict
the permeation
of a
®
significant
rise
in lipophilic
using synthetic
artificial
membranes
(cellulose
acetate, Strat-M
, Parallel Artificial
hydrophilic
and
compounds
such
as diclofenac,
hydrocortisone,
caffeine, amphotericin
B,
and capsaicin.
Results have
shown
that the Strat-M
had better
skin to
Membrane
Permeability
Assay
(PAMPA))
and 3-D® membrane
cultured human
skincorrelation
models asto
anhuman
alternative
with minimal
lot-to-lot
safety, and storage
limitations
[37–39]. Uchida
et al. evaluated
human
and animal
skinvariability,
in the development
of topical
and transdermal
formulations
[33]. Inthe
2018,
® membrane and compared them to
skin
permeabilities
of
13
chemical
compounds
using
Strat-M
European Medicines Agency’s draft guideline on quality and equivalence of topical products has
human and animal
skins.
Results confirmed
thattopermeability
coefficients,
andperformance
partition
recommended
the use
of synthetic
membranes
better understand
and diffusion,
characterize
®
well
correlated
the Strat-M
membrane
and human
animal skin
[33].
ofparameters
a finished were
topical
dosage
formbetween
[34]. Moreover,
synthetic
membranes
are and
inexpensive
and
easily
® membrane with human skin on permeation of
Recently,
Haq
et
al.
compared
the
Strat-M
nicotine.
®
resourced with superior data reproducibility [35,36]. Therefore, for our studies, Strat-M was used as
a diffusion membrane. Strat-M® is a multilayered synthetic membrane (300 µm thickness) similar
to skin and made up of several tightly-packed layers of polyester sulfone. Several studies have been
reported in the literature comparing the ability of Strat-M® membrane to predict the permeation of
hydrophilic and lipophilic compounds such as diclofenac, hydrocortisone, caffeine, amphotericin B,
and capsaicin. Results have shown that the Strat-M® membrane had better correlation to human skin
with minimal lot-to-lot variability, safety, and storage limitations [37–39]. Uchida et al. evaluated
the skin permeabilities of 13 chemical compounds using Strat-M® membrane and compared them to
human and animal skins. Results confirmed that permeability coefficients, diffusion, and partition

Pharmaceutics 2020, 12, 151

10 of 19

parameters were well correlated between the Strat-M® membrane and human and animal skin [33].
Recently, Haq et al. compared the Strat-M® membrane with human skin on permeation of nicotine.
Results showed that there was again a high correlation between human skin and Strat-M® with R2
Pharmaceutics
2020,
12, Hence,
x
12 of 19
value
of 0.99
[40].
we used Strat-M® as a diffusion membrane for our studies.

Cumulative amount permeated (μg/cm2)
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739.6 ± 36.1
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Figure 3. Cumulative amount of drug permeated from the formulations at the end of 24 h.

Formulation

Table 7. Cumulative amount, flux, and lag-time of drug permeated from the formulations at the end of
Figure 3. Cumulative amount of drug permeated from the formulations at the end of 24 h.
24 h (mean ± SD).

Table 7. Cumulative amount, flux,
and lag-time
of drug permeated from the formulations at the end
Cumulative
Amount
Lag-Time (h)
Flux (µg/cm2 /h)
of 24 hFormulation
(mean ± SD).
Permeated at 24 h (µg/cm2 )
Formulation
F1A
F1B
F2A
F2B
F3
F4
F5
F6

F1A Cumulative Amount 59.1
± 4.1 at 24 h (µg/cm2)2.70 ± 0.1
0.3
Permeated
Flux (µg/cm21.62
/h) ± Lag-Time
(h)
F1B
43.4
±
1.84
2.25
±
0.08
4.92
±
0.09
59.1 ± 4.1
2.70 ± 0.1
1.62 ± 0.3
F2A
163.2 ± 9.36
7.44 ± 0.41
No lag
43.4 ± 1.84
2.25 ± 0.08
4.92 ± 0.09
F2B
77.5 ± 5.4
3.63 ± 0.22
No lag
163.2 ± 9.36
7.44 ± 0.41
No lag
F3
320.8 ± 17.53
21.19 ± 0.94
1.05 ± 0.22
77.5 ± 5.4
3.63 ± 0.22
No lag
F4
82.0 ± 31.9
5.39 ± 1.37
5.17 ±1.5
320.8
±
17.53
21.19
±
0.94
1.05
F5
178.5 ± 34.5
7.41 ± 0.45
1.74 ± 0.67 ± 0.22
82.0
±
31.9
5.39
±
1.37
F6
739.6 ± 36.1
37.25 ± 5.1
2.37 ± 0.585.17 ±1.5
178.5 ± 34.5
7.41 ± 0.45
1.74 ± 0.67
739.6 ± 36.1
37.25 ± 5.1
2.37 ± 0.58

4.4.1. Effect of Mucoadhesive Agents (F1A vs. F1B and F2A vs. F2B)

4.5. Permeation
Analysiscomposition (Table 1), F1A and F1B, F2A and F2B had the same surfactant
As per the Data
formulation
system
and
concentration
of ibuprofen
but permeated
the only difference
was as
theaaddition
The cumulative amount
of ibuprofen
was plotted
functionofofmucoadhesive
time and the
agents
suchprofiles
as Tefose
in F1A
and HPMC
in formulations
F2A. Permeation
data
show that
addition
permeation
are 63
shown
in Figure
4. All the
showed
significant
lag the
in ibuprofen
of
mucoadhesive
agents
in
the
formulations
(F1A
and
F2A)
resulted
in
higher
permeation
of
permeation except F2A and F2B. This could be due to the presence of drug in solubilized form in F2A
2 vs. F1B: 43.4 ± 1.84 µg/cm2 and F2A: 163.2 ± 9.36 µg/cm2 vs.
ibuprofen
(F1A:
59.1
±
4.1
µg/cm
and F2B (Table 7).
77.5 ± 5.4 µg/cm2 ). Addition of mucoadhesive agents in the formulation could have resulted in
increased retention, prolonged contact, and reduced leakage of formulation and thus increasing the
permeation. Additionally, these agents increase level of hydration in the membrane interface which
in turn decreases the diffusional path length and thus favoring the transport of ibuprofen [24,41].
In addition, mucoadhesive agents could have increased the concentration gradient due to prolonged
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contact of the formulation at the membrane interface and resulting in enhanced permeation [42,43].
Addition of mucoadhesive agents could be advantageous in the development of topical formulations
intended for vaginal applications where bio-adhesion of mucoadhesive polymers, such as tefose 63
and HPMC, increase the retention and absorption of drugs [44–46].
4.4.2. Effect of Physical State of the Drug (F1A vs. F2A)
Physical state of drug in the formulation (solubilized vs. suspended) could significantly affect
the release of drug from the formulation. Polarized light microscopy (Figure 2) revealed that even
though ibuprofen concentration was the same (3% w/w) in F1A and F2A, drug was in solubilized
form in F2A and suspended form in F1A. Permeation results show that cumulative amount of drug
permeated at the end of 24 h was significantly higher in F2A compared to F1A (163.2 ± 9.36 µg/cm2
vs. 59.1 ± 4.1 µg/cm2 ). Enhanced permeation in F2A could be attributed to increased thermodynamic
activity with the solubilized formulation. Additionally, ibuprofen could have been dissolved in the oil
phase resulting in no dispersed drug particles in the formulation. Thus, solubilized drug increased the
partition into the membrane and thus resulted in enhanced permeation [16]. These types of systems
are suitable for enhanced permeation of lipophilic drugs, like ibuprofen, which tend to dissolve in the
oil phase and partition across the skin.
4.4.3. Effect of Drug Concentration in the Formulation (F1A vs. F3 and F2A vs. F4)
F1A vs. F3
As per the formulation composition table provided in the earlier section (Table 1), F1A and F3 had
the same surfactant system to stabilize the formulation, but F3 had higher concentration of drug (5%
w/w) compared to F1A (3% w/w). Polarized light microscopy results revealed that ibuprofen existed
in a suspended form in both the formulations (Figure 2). As expected, permeation data showed that
cumulative amount of drug ibuprofen permeated at the end of 24 h was significantly higher with F3
compared to F1A (320.8 ± 17.53 µg/cm2 vs. 59.1 ± 4.1 µg/cm2 ). Enhanced permeation of ibuprofen
could be attributed to the higher concentration of ibuprofen in F3, which acted as a reservoir and
helped in maintaining concentration gradient for a prolonged period [19]. These types of systems
should be considered for drugs that require high doses, such as NSAIDs (ibuprofen and diclofenac)
and lidocaine, where the goal is to achieve maximum flux across the skin for improving efficacy.
F2A vs. F4
As per the formulation composition table (Table 1) provided in the earlier section, F2A and F4
had the same surfactant system to stabilize the cream formulation but F4 had higher concentration
of drug (5% w/w) compared to F2A (3% w/w). Polarized light microscopy results revealed that
ibuprofen existed in a suspended form in F4 and solubilized form in F2A (Figure 2). Interestingly,
permeation results showed that although F4 had higher ibuprofen concentration compared to F2A
(5% w/w vs. 3% w/w), cumulative amount of drug permeated at the end of 24 h was less compared
to F2A (82.0 ± 31.9 µg/cm2 vs. 163.2 ± 9.36 µg/cm2 ). Enhanced permeation with F2A formulation
could be attributed to increased thermodynamic activity and partition of the solubilized drug in
the formulation [47]. Solubilized systems are preferred for highly-potent drugs such as fentanyl,
progesterone, and testosterone, requiring very less concentration of drug for activity. Formulations
with highly-potent drugs have a high risk if there is residual drug leftover after the intended use
period, which may impact the product’s quality, efficacy, and safety. Recently USFDA has released a
guidance on minimizing the residual drug in the formulations. One of the recommendations was to
design formulations with optimal drug delivery and minimal residual drug [48]. Thus, the approach
of using systems with solubilized drugs could minimize the residual drug and maintain the desired
permeation rate of drugs throughout the usage period.
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4.4.4. Effect of Formulation Type
Solubilized Cream vs. Non-Aqueous Gel (F6 vs. F2A)
Although the concentration of ibuprofen was similar and the drug was in solubilized form in
formulations F6 and F2A, cumulative amount of drug permeated was significantly higher with gel
compared to solubilized cream (F6: 739.6 ± 36.1 µg/cm2 vs. F2A: 163.2 ± 9.36 µg/cm2 ). Enhanced
permeation could be due to low viscosity of the gel which resulted in high drug release from the
formulation. Moreover, higher concentration of permeation enhancers in the formulation could have
increased the solubility of ibuprofen and enhanced the diffusivity across the membrane.
Emulgel vs. Cream (F5 vs. F1A and F2A)
Permeation data show that cumulative amount of drug permeated at 24 h was higher with emulgel
even though ibuprofen was available as suspended form in the formulation (F5: 178.5 ± 34.5 µg/cm2
vs. F2A: 163.2 ± 9.36 µg/cm2 vs. F1A: 59.1 ± 4.1 µg/cm2 ). Emulgels, also known as emulsified gels,
are biphasic systems, containing aqueous gel dispersed with lipid phase, and are closely related to
cream. It is reported in the literature that emulgels provide better solubility for poorly water-soluble
drugs like ibuprofen and enhance the skin permeability. Higher permeation of ibuprofen with emulgels
compared to creams could be attributed to increased thermodynamic activity of ibuprofen, due to
a change in the vehicle where ibuprofen was more soluble, or due to a different interaction of the
formulation with the membrane [24,49,50].
Clear Gel vs. Emulgel (F6 vs. F5)
At the end of 24 h, significantly higher amount of ibuprofen was permeated across the membrane
with clear non aqueous gel (739.6 ± 36.1 µg/cm2 ) compared to emulgel (178.5 ± 34.5 µg/cm2 ). Although,
concentration of ibuprofen in the formulation was similar in both the formulations, low viscosity and
presence of ibuprofen in solubilized form in the gel formulation resulted in enhanced permeation.
As discussed earlier, low viscosity of the clear gel resulted in greater permeation due to immediate
and higher release of ibuprofen from formulation. Additionally, high thermodynamic activity and
partition of ibuprofen could have resulted in enhanced permeation.
4.5. Permeation Data Analysis
The cumulative amount of ibuprofen permeated was plotted as a function of time and the
permeation profiles are shown in Figure 4. All the formulations showed significant lag in ibuprofen
permeation except F2A and F2B. This could be due to the presence of drug in solubilized form in F2A
and F2B (Table 7).
4.6. Physical Stability
All the formulations were stored at 25 ± 2 ◦ C and 40 ± 2 ◦ C to observe any changes in the physical
stability. As shown in the Figure 5, there were no observable changes in color and stability (phase
separation, creaming, crystallization, and phase inversion) of all creams and gels. This suggests that all
the formulations were physically stable throughout the storage period at both temperatures.
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4.6. Physical Stability
All the formulations were stored at 25 ± 2 °C and 40 ± 2 °C to observe any changes in the physical
stability. As shown in the Figure 5, there were no observable changes in color and stability (phase
separation, creaming, crystallization, and phase inversion) of all creams and gels. This suggests that
all the formulations were physically stable throughout the storage period at both temperatures.
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5. Conclusions
Formulation of a topical drug product for lipophilic drugs with desirable QTPP is challenging.
Several factors such as physicochemical properties of the drug, formulation parameters, excipients in
the formulation, and other parameters can affect the permeation profile. For successful topical
product development, a thorough understanding of the impact of these factors on product
performance is required. This study gives an example of a screening study approach that evaluates
several excipients and formulation variables on product performance. It is already known that active
drug accounts only for a minor fraction in the formulation and; therefore, it is important to
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5. Conclusions
Formulation of a topical drug product for lipophilic drugs with desirable QTPP is challenging.
Several factors such as physicochemical properties of the drug, formulation parameters, excipients in
the formulation, and other parameters can affect the permeation profile. For successful topical product
development, a thorough understanding of the impact of these factors on product performance is
required. This study gives an example of a screening study approach that evaluates several excipients
and formulation variables on product performance. It is already known that active drug accounts only
for a minor fraction in the formulation and; therefore, it is important to understand how the excipients
within the formulation interact with the active drug and influence the permeation. The aim of the
present study was to investigate the effect of formulation parameters, such as concentration of drug,
physical state of the drug, addition of mucoadhesive agents, and formulation type, on permeation of
ibuprofen from semisolid formulations. For this, we successfully developed eight different semisolid
formulations (creams, emulgel and gel) of ibuprofen and evaluated the effect of formulation parameters
on the in-vitro permeation. All the formulations were of acceptable quality and remained physically
stable over a period of 90 days at room temperature and 40 ◦ C. Results from the present investigation
noted considerable differences in permeation of ibuprofen across the Strat-M® membrane due to
significant influence of formulation parameters, including concentration of ibuprofen (3% vs. 5% w/w),
physical state of ibuprofen (solubilized vs. suspended), formulation type (cream vs. gel), mucoadhesive
agents, and viscosity (high vs. low). It is clear according to the permeation profile that F6 (3% w/w
ibuprofen clear non-aqueous gel) had the highest permeation rate among all formulations evaluated.
Thus, findings from this study indicate that pharmaceutical formulation scientists should explore
these critical factors during the early development of any new topical drug product in order to meet
pre-determined QTPP. Additionally, as the majority of the NSAIDs have similar physicochemical
properties, this article could serve as a ready reference to formulation scientists for selection of the
formulation type to achieve desirable permeation profile.
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Appendix A
Optimization of Formulations
Results for the optimization of ibuprofen formulations are provided in Tables A1–A3. The goal of
the optimization experiments was to formulate creams and gels with acceptable appearance, viscosity,
and stability. During optimization, it was observed that several formulations had issues with stability,
excipient incompatibility, and viscosity. Thus, the formulations with these issues were dropped and
reformulated by changing the excipient concentration to achieve optimized formulations (Tables A1–A3)
with desired qualities for further studies.
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Table A1. Optimization of cream formulations.
Components

Formulation Trial (%w/w)
1

2 (F1A)

3 (F1B)

4

5 (F2A)

6 (F2B)

7

8 (F3)

9

10 (F4)

Ibuprofen

3

3

3

3

3

3

5

5

5

5

Propylene glycol

15

15

15

-

-

-

-

-

-

-

Oleyl alcohol

-

-

-

5

5

5

-

-

-

-

Isopropyl Myristate

-

-

-

-

-

-

10

10

-

-

Transcutol

-

-

-

-

-

-

-

-

15

15

Mineral oil

10

10

10

-

-

-

7

7

-

-

White petrolatum

-

-

-

10

10

10

-

-

-

-

Polyethylene glycol 400

-

-

-

-

-

-

10

10

-

-

Medium chain triglycerides

-

-

-

-

-

-

-

-

10

10

Glycerol

-

-

-

-

-

-

-

-

3

5

Span 20

3.8

3.8

3.8

-

-

-

4.6

4.7

-

-

Kolliphor Polysorbate 80

3.3

3.3

3.3

-

-

-

2.1

1.3

-

-

Kolliphor CS 20

-

-

-

4.1

4.1

4.1

-

-

5

5

Glycerol monostearate

-

-

-

2.5

2.5

2.5

-

-

1.1

1.1

Cetyl alcohol

4

7

7

-

-

-

-

-

4

7

Stearyl alcohol

-

-

-

5

10

10

-

-

-

-

Cetostearyl alcohol

-

-

-

-

-

-

-

5

-

-

Sepineo SE68

3

5

5

-

-

-

-

-

-

-

Sepineo P600

-

-

-

-

-

-

4

4

-

-

Tefose 63

3

5

-

-

-

-

7

8

-

-

HPMC

-

-

-

-

1

-

-

-

-

-

Carbopol 974

-

-

-

-

-

-

-

-

0.5

0.5

Water

54.9

47.9

52.9

70.4

64.4

65.4

50.3

45

56.4

51.4

Observation

Emulsion
was not
stable

Thick white
cream with
no signs of
separation

Less viscous
white cream
with no
signs of
separation

Less viscous
cream with
physical
instability

Stable white
cream with
no signs of
separation

Smooth
white cream
with no
signs of
separation

Physical
instability
was
observed

Stable
emulsion
with no
signs of
instability

Physical
instability
was
observed

Stable cream
with no
signs of
separation
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Table A2. Optimization of emulgel formulation.
Formulation Trial (%w/w)

Components

1

2

3 (F5)

Ibuprofen

3

3

3

Ethanol

10

20

30

Sepineo P600

4

4

4

Water

83

73

63

Observation

Physical instability. Precipitation of
ibuprofen in the formulation

Slight precipitation of ibuprofen in the
formulation

Translucent gel with acceptable viscosity

Table A3. Optimization of clear gel formulation.
Components

Formulation Trial (%w/w)
1

2

3

4

5

6

7

8

9

Ibuprofen

3

3

3

3

3

3

3

3

3

10 (F6)
3

Propylene glycol

15

5

15

15

15

15

15

15

15

15

10

10

10

15

15

15

Ethanol

-

-

-

-

10

10

Transcutol

5

15

15

15

15

15

15

HPMC

1.5

-

1.5

-

1.5

-

1.5

-

-

-

HPC

-

-

-

-

-

-

-

1.5

3

4

Carbopol 974

-

1.5

-

1.5

-

1.5

-

-

-

-

Polyethylene glycol 400

-

-

-

-

-

-

75.5

55.5

54

53

Water

75.5

75.5

65.5

65.5

55.5

55.5

-

-

-

-

Observation

Precipitation of
drug was
observed. Gel
was not clear gel

Precipitation of
drug was
observed. Gel
was not clear gel

Precipitation of
drug was
observed. Gel
was not clear gel

Precipitation of
drug was
observed. Gel
was not clear gel

Precipitation of
drug was
observed. Gel
was not clear gel

Precipitation of
drug was
observed. Gel
was not clear gel

HPMC was not
dissolved in
PEG 400

Gel was
clear but not
viscous

Gel was
clear but not
viscous

Clear gel with
acceptable
viscosity
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